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Abstract Various screening tools have been proposed to iden-
tify HIV-Associated Neurocognitive Disorder (HAND). How-
ever, there has been no systematic review of their strengths and
weaknesses in detecting HAND when compared to gold stan-
dard neuropsychological testing. Thirty-five studies assessing
HAND screens that were conducted in the era of combination
antiretroviral therapy were retrieved using standard search pro-
cedures. Of those, 19 (54 %) compared their screen to standard
neuropsychological testing. Studies were characterised by a
wide variation in criterion validity primarily due to non-
standard definition of neurocognitive impairment, and to the
demographic and clinical heterogeneity of samples. Assess-
ment of construct validity was lacking, and longitudinal
useability was not established. To address these limitations,
the current review proposed a summary of the most sensitive
and specific studies (>70 %), as well as providing explicit
caution regarding their weaknesses, and recommendations for
their use in HIV primary care settings.
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Introduction
The introduction of combination antiretroviral therapies
(cART) has changed Human Immunodeficiency Virus (HIV)/
Acquired Immunodeficiency Syndrome (AIDS) from a life
threatening disease to one that is chronic [1]. Since the intro-
duction of cART, HIV-associated neurocognitive disorder
(HAND) has remained one of the main central nervous system
complications in HIV infection, with its prevalence remaining
stable at 30-50 % from the pre- to post- cART era [2–4]. This
overall stability has in part been attributed to the increased
lifespan associated with receiving cART [5] as well as the
chronic effects of HIV on the brain [6•]. Despite this overall
stability, however, the more severe form of HAND, dementia,
has been attenuated by cART, and mild forms of HIV-related
neurocognitive impairment are now more common [7••].
This epidemiological shift prompted neuroHIV experts to
reformulate the original HANDdiagnostic criteria [8, 9] to better
discriminate between demented and non-demented forms of the
disease. As a result, the current American Academy of Neurol-
ogy (AAN) HAND diagnostic classification criteria categorise
three degrees of severity: mild (Asymptomatic Neurocognitive
Disorder; ANI), moderate (Mild Neurocognitive Disorder;
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MND), and severe (HIV-Associated Dementia; HAD) [10]. As
the critical feature that distinguishes MND from ANI is the
presence of significantly declined instrumental activities of daily
living (IADL), accurate assessment of IADL status is imperative
to diagnosis [10].
Themajority ofHIVpositive (HIV+) individualswithHAND
in the cART era do not present with HAD [11••]. It is therefore
only through comprehensive neuropsychological assessment that
ANI/MND are revealed [12•]. If not treated early, these non-
demented forms ofHANDhave been found to be a risk factor for
HAD [13]. Having mild HAND also yields a greater chance of
developing future cognitive difficulties, particularly as HIV+
individuals age [14]. Early detection through screening is there-
fore imperative to minimise progression of ANI/MND to HAD,
at which point there is likely less chance of complete recovery,
even after cART is initiated. Accurate detection is also crucial to
therapeutic and clinical care of those with HAND, particularly
for ANI, as it enables adequate follow up in HIV+ individuals
who would otherwise not be targeted for neurological care.
Although comprehensive neuropsychological assessment is
the recommended gold standard for detectingHAND, cognitive
screening measures such as the HIV Dementia Scale (HDS)
[15] have been suggested when time and resources are limited
[10]. As not all HIV+ individuals develop HAND, an initial
brief screen followed by a comprehensive neuropsychological
assessment in only those with an impaired screen is a cost-
effective strategy that has previously been proposed [16••]. This
strategy is only useful however, if the screen is able to detect at
least mild HAND with adequate sensitivity and specificity.
Valcour and colleagues [17••] recently summarised
existing HAND screens, however their review was not ex-
haustive and did not differentiate between those validated in
pre-cART versus cART samples or against a gold standard
neuropsychological assessment. More recently, a systematic
review [18••] was conducted, although it was limited to the
screening accuracy of the HDS and International HDS, and
calculation excluded those with ANI, the most common form
of HAND. To our knowledge, no study to date has systemat-
ically reviewed the criterion and construct validity of all
existing cART era HAND cognitive screening studies under
comprehensive methodological constraints. A review of this
nature would establish a precedent in laying out the detailed
strengths and limitations of the validation procedures that
have been conducted, and hence the practical useability of
existing screens in the cART era. Such a review would also
serve as the basis for defining guidelines for improved vali-
dation strategies.
Based on this need, the aims of the current review were to:
1. Provide a systematic review of all HAND screening in-
struments in the cART era that have been assessed against
standard neuropsychological testing as gold standard.
2. Critically review the findings, with particular attention to
the validation procedure, base impairment rate, and crite-
rion and construct validity.
3. Guide researchers and clinicians towards an informed
screen selection, and to delineate recommendations for
an improved screen validation.
Methods
Seven databases were searched between June 2012 and May
2013, including Pubmed, psycINFO, Cochrane Library Data-
bases, Scopus, and ScienceDirect. Each database was searched
(keyword/title/abstract) using the following keywords: HIV
and cognitive/neurcognitive/neuropsych*/computer* and
screen*/test/battery and HAART/cART. The reference lists of
included articles were also examined for eligible studies. After
each search was completed, all returned abstracts were
extracted, and duplicates removed.
As indicated in Fig. 1, the search returned 242 abstracts.
Studies were excluded if:
& Written in a language other than English,
& Not a published peer-reviewed original research article
(e.g. review, commentary or conference abstracts),
& It was not stated whether HIV+individuals had received
cARTorwere conducted in the pre-cARTera (prior to 1996),
& A cognitive screeningmeasure that assessed HIV-associated
cognitive impairment was not included;
& The mean age of participants was below 18 years.
As outlined in Fig. 1, full text of 35 articles was retrieved.
Of those, a further 14 were removed after consultation of the
full text due to the following reasons: they did not compare the
screen to a gold standard comprehensive neuropsychological
assessment, the gold standard used was other than neuropsy-
chological tests, the sample derived from the pre-cART era,
and no screen was used. An additional study [19] was exclud-
ed as it used a sub-sample of another study [20]. Based on a
manual search of the reference lists of retrieved articles, six
abstracts of interest were retrieved and subsequently excluded
(see Fig. 1). Each of the final 19 studies was systematically
reviewed in a non-blind fashion, and data was extracted.
As the study methods and designs, and type of screening
measure used varied substantially between the 19 studies, a
systematic review was conducted rather than a meta-analysis.
For each study in the review, the cognitive domains and
specific items of the screening measures and NP gold standard
were summarised. Sample characteristics were then presented
for the HIV+ and HIV - groups using summary statistics
including medians and ranges where appropriate. Next, im-
pairment classification criteria and rate were summarised for
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the neuropsychological gold standard and screening measures
using medians and ranges. Finally criterion and construct
validity were examined andmedians and ranges were reported.
Results
The 19 empirical papers were published between 2003 and
2013. All but one were cross-sectional in design; one study
[21] computed criterion validity indexes at baseline and eval-
uated stability at 12 weeks and 24 weeks follow-up, although
longitudinal results were not reviewed here. See Online
Resource 1 for a comprehensive overview of all 19 studies.
HAND Screening Measures
Of the 19 studies, 17 compared the utility of one screen to a
gold standard (comprehensive neuropsychological testing),
one evaluated three screens [22], and two studies compared
two screens [23, 24]. Three studies used computerised
screens. One study [25] used the original CogState battery
that assesses psychomotor speed, attention and working mem-
ory, and visual learning and memory. Another study [21] used
the Computerised Assessment of Mild Cognitive Impairment
(CAMCI) [26], an eight task battery assessing attention,
psychomotor speed, working memory, learning and memory,
and executive function (inhibition). The final computerised
study [27] used the CalCAP Mini Battery [28], which targets
one domain, psychomotor speed/reaction time, through two
tasks. The most common paper and pen screen was the HDS
(n= 10), followed by the IHDS (n =5) [29]. Four studies used
combinations of standardised neuropsychological tests; one
Mexican study [24] used a large neuropsychological battery
to assess the domains of orientation, attention, memory, lan-
guage, visuospatial abilities, and executive functions through
16 tests, the remaining studies used smaller combinations (e.g.
two, three or four) of neuropsychological tests [23, 30, 31].
Neuropsychological Gold Standard
All but one study [21] specified the individual tests used in the
gold standard test battery. One study [29] included two samples
that used a different battery of neuropsychological tests as the
gold standard and were considered separately, generating a total
of 20 reviewed studies. Comprehensiveness of the gold standard
neuropsychological test battery varied widely across studies in
terms of the domains assessed (see Table 1). Eight cognitive
domains were assessed across the 20 studies. These included
premorbid ability (not included in impairment rate), motor/fine
motor skills, attention and working memory, psychomotor
Number of articles retrieved 
N = 242
Excluded (n = 207)  
Not peer reviewed original research article          101 
No screen measure            67 
Did not state if used triple combination therapy or  
was conducted in Pre-cART era            34  
Mean age below 18 years              4  
Non-English              1 
Titles and abstracts screened
Articles retrieved and full text 
screened  n = 35
Contained sub-sample of another 
larger study n=1
Articles obtained from reference 
lists n = 6
Included for review n = 19
Excluded (n = 14)  
Did not compare screen to gold standard             6 
Gold standard was other than neuropsychological tests   4 
Sample from the pre-cART era             3 
No screen was used             1 
Excluded (n = 6)  
Not peer reviewed original research article             4 
Pre-cART era             1 
Gold standard was other than neuropsychological tests   1 
Fig. 1 Flow diagram of study
selection
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speed/reaction time, learning and memory, executive function,
language, and visuoconstruction. No single study assessed all
domains; instead, the median was five (range=3-7). The most
frequently assessed domain was information processing speed/
reaction time, with all studies using at least onemeasure, follow-
ed by executive function (n=18), learning and memory (n =17)
and motor/fine motor skill (n=17). Ten studies used a measure
of both verbal and visuospatial memory.
All studies that included a measure of motor/fine motor
skill used the Grooved Pegboard. The Paced Auditory Serial
Addition Test and Digit Span were the most frequently used
measure of attention and working memory (both n =6), as was
the Trail Making Test A (n =13) for information processing
speed/reaction time. TrailMaking Test B (n =12) was the most
common measure of executive function. Within the verbal
domain of learning and memory, the most frequently used
task of verbal learning and memory was the Hopkins Verbal
Learning Test (n =6), and the Brief Visuospatial Memory Test
for visuospatial learning and memory (n =6). Semantic fluen-
cy was the preferred measure of language (n =6), and the Rey
Complex Figure copy the most commonly employed test of
visuoconstruction (n =3). Two studies [32, 33] also included
general screening measures in the neuropsychological gold
standard test battery.
Sample Characteristics
Details of exclusion criteria, demographic characteristics for
HIV+and HIV-negative (HIV-) groups, and HIV infection
characteristics can be consulted in Online Resource 1. In brief,
studies varied considerably in their exclusion criteria, sample
size, population, country location, demographic composition
and HIV-specific features, such as years since diagnosis, CD4
cell count, viral load, and proportion receiving cART or with
AIDS. The main sample source was tertiary referral. One
study recruited a sample from a primary health care centre
[34], one used a sample of US military beneficiaries [31], and
four studies did not report their sample source. Thirteen stud-
ies were conducted in a Western country, four in non-Western
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NART=National Adult Reading Test; GP=Grooved Pegboard; FT= Finger Tapping; FO = Finger Oscillation; TG = Timed Gait; LNS = Letter Number
Sequencing; PASAT = Paced Auditory Serial Addition Test; SpWM = Spatial Working Memory, CANTAB; SeqRT = Sequential Reaction Time,
CalCAP; VisSp = Visual Span; TMTA= Trial Making Test A; CT1 = Colour Trails Test 1; SS = Symbol Search; SDMT = Symbol Digit Modalities Test;
RT = Reaction Time, CANTAB; VIP = Visual Information Processing, CANTAB; VCRT = Visual Choice Reaction Time; HVLT = Hopkins Verbal
Learning Test; BVMT = Brief Visuospatial Memory Test; SMLT = Story memory Learning Test; FMLT = FigureMemory Learning Test; RAVLT = Rey
Auditory Verbal Learning Test; CVLT = California Verbal Learning Test; RCFT 3 min = Rey Complex Figure Test, 3 Minute Delay; VLT = World
Health Organisation /University of California Verbal Learning Test;MAT –Mental Alternation Test;MCT=Mental Control Test; CT2 =Colour Trails 2;
CWT = Stroop Colour Word Interference Test; WCST = Wisconsin Card Sort Test; LetFl = Letter Fluency; ActFl = Action Fluency; TMTB = Trail
Making Test B; HCT=Halstead Category Test; SemFl = Semantic Fluency; BNT =Boston Naming Test; RCFTCopy = Rey Complex Figure Test Copy
“X” = Test not specified
a verbal and visuospatial learning and memory
b Individual tests not specified, assumed that the whole battery was administered
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Impairment Classification Criteria and Rate
There was considerable heterogeneity in the methods used to
calculate the overall impairment rate for the neuropsycholog-
ical gold standard and screening measures. Of the 20 separate
studies, seven explicitly reported the gold standard overall
impairment rate, whilst 13 provided sufficient information
for it to be calculated. In terms of impairment classification
method, criteria for nine analyses were solely based on neu-
ropsychological test scores, with one study reporting poorly
defined impairment criteria (i.e. moderate cognitive impair-
ment: “beyond the norms on at least two tests” without spe-
cific reference to the normative sample or cut-off criterion)
[35]. Eleven analyses used clinical ratings that incorporated
neuropsychological test scores, neurological information,
brain imaging, and functional ability to classify individuals.
Of those, ten used a version of the AAN criteria, and one used
a system based on the Memorial Sloan Kettering (MSK)
dementia scale [36], which contains gradations that range
from minor cognitive disturbance to profound and incapaci-
tating disorders, and integrates neurological deficits related to
myelopathy. There was considerable disparity across studies
regarding whether asymptomatic or subclinical cognitive im-
pairment was considered in the overall impairment rate. While
five studies [20, 24, 33, 37, 38] included this group as cogni-
tively ‘impaired’, three studies [21, 22, 35] considered those
individuals as ‘unimpaired’, and another [29] explicitly ex-
cluded this group from analysis. Conversely, a further study
[39] excluded those with moderate to severe dementia from
their sample. Considering the heterogeneity of the term ‘im-
pairment’ and varying methods for classification, impairment
rates based on the neuropsychological gold standard ranged
widely across studies, from 19 % to 81 % (median=51 %).
In most instances studies generated multiple screen impair-
ment ratings associated with the use of more than one screen
or multiple methods for generating impairment (by varying
cut-offs or including only a subset of the overall sample),
generating 55 analyses see (Table 2). In general, screen-
based impairment rate was poorly reported across studies. It
was explicitly stated in one fifth, and six provided sufficient
detail so that it could be calculated. Two thirds of the studies,
however, failed to report the impairment rate or provide infor-
mation to permit calculation. Across the 18 available analyses,
median impairment rate was 33 % (range =4-71 %). In direct
comparison to the neuropsychological gold standard, impair-
ment for all screening measures was classified using test
scores only; no IADL measure was used.
Criterion Validity
In most instances studies generated multiple criterion validity
indexes based on varying cut-off scores, demographic adjust-
ments, and on different subsamples of the overall sample,
generating a total of 55 analyses (presented in Table 2). Across
all 55 screen analyses, sensitivity (the proportion of individ-
uals identified as impaired on both the gold standard and the
screen) ranged widely between 0 % and 93 % (median=
66 %). Specificity (the proportion of individuals identified as
unimpaired on both the gold standard and the screen) ranged
between 25 % and 100 % (median=80 %). Overall classifica-
tion accuracy was reported in 20 % (n =12) of the analyses,
and ranged between 42 % and 87 % (median=65 %). Ten
analyses (18 %) produced sensitivity and specificity over
70 %, and were ranked in order from highest to lowest
sensitivity in Table 3. Twenty-five analyses (45 %) used
standard raw cut-off criterion (≤10) for the HDS/IHDS, and
14 (25 %) analyses were based on subsets of larger samples.
In regards to varying levels of HAND severity, one study
[20] that used the HDS found sensitivity decreased with the
inclusion of milder HAND (77%moderate-severe impairment,
65 % mild-moderate impairment, 63 % mild impairment).
Another study [40] generated HDS criterion validity for
HAD, MND, and ANI, separately and found sensitivity was
36 %, 23 %, 0 %, respectively, as compared to 17 % for the
overall sample. Yet another [24] found 100 % of those diag-
nosed as ANI by the neuropsychological gold standard were
misclassified when using theMMSE, and 50%when using the
HDS and NEUROPSI. Similarly, the IHDS was found not to
distinguish between those who were subclinical (MSK=0.5)
and those whowere cognitively ‘unimpaired” (MSK=0) across
America and Ugandan samples [29]. By removing those who
were diagnosed by the neuropsychological gold standard as
ANI from the ‘impaired’ group, categorising them as
‘unimpaired’ and comparing this group to those with moderate
to severe impairment (MND/HAD), sensitivity markedly im-
proved for the IHDS (45 % to 81 %;[34]), but less so for the
HDS (67 % to 70 %), and NEUROPSI (75 % to 80 %), and
least of all for the Mini Mental Status Examination
(MMSE; 8 % to 10 %). Lastly, for the HDS to be sensitive
to milder forms of HAND, the cut-off was required to be
raised to a score of 12 [33] or 14 or less [37].
By using demographic adjustments (T <40), the HDS
was shown to improve markedly in sensitivity as com-
pared to the standard raw cut-off (≤10) for each level of
HAND severity (HAD: 36 %-93 %; MND: 23 %-77 %;
ANI: 0 %-50 %; [40]), andwas associatedwith amarked yet
acceptable decrease in specificity (from 94 % to 73 %). Indeed,
seven out of the top ten screens with the highest sensitivity used
demographically adjusted cut-off scores, and all screens that used
short combinations of NP tests (20 %) used demographically
adjusted cut-off criterion.
Three studies investigated concomitant criterion validity
of several screens. One study [24] compared the utility of
three screens using the same sample and found that none
exhibited optimal values for both sensitivity and specific-
ity, and the MMSE performed particularly poorly when
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Table 2 Screen versus gold standard NP impairment rates and standard criterion validity indexes across studies (%)
Study Screen NP IR Screen IR Cut-off Sub-sample Sensitivity Specificity Accuracy
[40] Morgan HDS 43a - T<40 HAD only 93 73 -




or 1 test T<40 +
1 test T<30,
or 1 test T<25




[25] Cysique CogState 62c 62c - - 81 70 -
[23] Carey NP tests
(HVLT-R& ndGP)
29c 34c T<40 on 1 test or - 78 85 83
T<35 on 2 tests
[40] Morgan HDS 43c - T<40 MND only 77 73 -
[23] Carey NP tests
(HVLT-R& Cod)
29c - T<40 on 1 test or - 75 92 87
T<35 on 2 tests
[31] Moore 2 NP tests 19c - 2 tests T<40 or - 73 83 -
1 test T≤35
[29] Sacktor IHDS(American) 38c - ≤10.5 - 71 79 -
[21] Becker CAMCI 31c 30c - -g 72 98 -
[35] Singh IHDS 80c,f - ≤10.5 - 94 25 -
[32] Bottiggi HDS 52c - ≤10 - 93 38 -
[33] Simioni HDS 74c - ≤14 No self reported 88 67 -
cognitive complaints
[35] Singh IHDS 80c,f - ≤10 - 88 50 -
[29] Sacktor IHDS (Ugandan) 31c - ≤9.5 - 88 48 -
[37] Wonja HDS 68b 48b,e ≤13 - 87 46 -
[38] Chalermchai IHDS 51c - ≤10 - 86 - -
[33] Simioni HDS 74c - ≤14 Self reported cognitive
complaints
83 63 -
[34] Joska IHDS 81b - ≤11 - 81 54 -
[29] Sacktor IHDS (American) 38b - ≤10 - 80 57 -
[22] Skinner IHDS 40b - ≤10 - 77 65 70
[20] Sakamoto HDS 51c 12b ≤10 moderate-severe
impairment
77 - -
[24] Levine NP tests 52b 71c T score (varied) - 75 61
[20] Sakamoto HDS 51c 56c T<40 - 69 56 63
[27] Gonzalez CalCAP 57c 49c Average deficit - 68 77 72
[24] Levine HDS 52b 62c ≤10 - 67 50 -
[20] Sakamoto HDS 51c - ≤14 - 66 61 -
[20] Sakamoto HDS 51c - ≤10 virologically
suppressed only
66 55 61
[20] Sakamoto HDS 51c 19b ≤10 mild-moderate impairment 65 - -
[37] Wonja HDS 68b 48b,e ≤12 - 63 84 -
[20] Sakamoto HDS 51c 20b ≤10 mild impairment 63 - -
[22] Skinner HDS 40b - ≤11 - 62 80 -
[30] Ellis 3 NP tests 56c,d - Averaged z-scores≤0.5 - 58 82 68
[32] Bottiggi HDS 52c - ≤10 Moderate & severe impairment 57 84 -
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compared to the HDS and NEUROPSI. Similarly, another
study [22] compared the utility of the HDS and IHDS
within the same sample and found that while the HDS
showed the highest sensitivity (76.9 % versus 46.2 %),
the IHDS had superior specificity (65 % versus 55 %).
One study [23] showed that within their sample, the pairing
of the Hopkins Verbal Learning Test Recall and Grooved
Pegboard non-dominant scores drastically outperformed
the HDS in terms of sensitivity (78 % versus 9 %), though
demonstrated inferior specificity (85 % versus 98 %). Of
note, an additional study found the IHDS to increase by
30 % (53.3 % vs 86 %) with the inclusion of Trail Making
Test part A [38].
Lastly, one study [20] that used the HDS with standard cut-
off criterion found that by including only those in the sample
who were viruologically suppressed, sensitivity and overall
classification accuracy were raised (24% to 66%, and 57% to
61 %, respectively), although this was associated with a
decreased in specificity (92 % to 50 %).
Construct Validity
Only three studies reported correlations between their respec-
tive screening measure and neuropsychological tests and/or
cognitive domains (see Table 4). Very small to moderate
associations were observed generally across these studies
and no screen was clearly primarily related to neuropsycho-
logical tests associated with core HAND domains (e.g. infor-
mation processing speed or attention and working memory).
In many instances although significant correlations were
Table 2 (continued)
Study Screen NP IR Screen IR Cut-off Sub-sample Sensitivity Specificity Accuracy
[45] Richaradson HDS 50c 40c ≤10 - 55 75 63
[33] Simioni HDS 74c - ≤10 - 54 96 -
[38] Chalermchai IHDS 51c - ≤10 - 53 89 -
[40] Morgan HDS 43b - T<40 ANI only 50 73 -
[22] Skinner HDS 40b - ≤10 - 46 80 67
[22] Skinner MMSE 40b - ≤27 - 46 55 -
[34] Joska IHDS 81b - ≤10 - 45 80 56
[30] Ellis 3 NP tests 56c,d 32c ≤1 SD 1 test - 44 84 -
[39] Smith HDS 49b - ≤10 - 39 85 -
[40] Morgan HDS 43b - ≤10 HAD only 36 94 -
[32] Bottiggi HDS 52c - ≤10 Severe impairment only 36 94 -
[38] Chalermchai IHDS 51c - ≤10 - 34 87 -
[30] Ellis 3 NP tests 56c,d 15c ≤1 SD on 1 test / ≤ 2
SD on 2 tests
- 24 98 -
[20] Sakamoto HDS 51c 17c ≤10 - 24 92 57
[40] Morgan HDS 43b - ≤10 MND only 23 94 -
[40] Morgan HDS 43b - ≤10 - 17 94 -
[23] Carey HDS 29b 4b ≤11 - 9 98 -
[24] Levine MMSE 52b 14c ≤25 - 8 88 -
[30] Ellis 3 NP tests 56c,d - Clinical rating ≥5 - 2 100 42
[40] Morgan HDS 43b - ≤10 ANI only 0 94 -
N=55 Median
Range
51 33 66 80 65
19-81 4-71 0-93 25-100 42-87
See reference list for numbered studies. Rounded to nearest whole value. Ordered with balance of highest sensitivity and specificity. Studies with ≥70 %
sensitivity and specificity are bold. Studies≤70 % sensitivity and specificity are in grey. Values are based on standard cutoff scores unless otherwise
stated. Values represent percentages unless otherwise stated, and are to the nearest decimal reported. NP = neuropsychology. IR = Impairment rate. HDS
= HIV Dementia Scale. NP = neuropsychological. HVLT-R = Hopkins Verbal Learning Test, Revised. ndGP = non-dominant hand Grooved Pegboard.
Cod = Coding. IHDS = International HIV Dementia Scale. MMSE = Mini Mental Status Exam. Accuracy = classification accuracy. ‘-‘ = not reported.
Sensitivity refers to the proportion of individuals identified as impaired on both the gold standard and the screen. Specificity refers to the proportion of
individuals identified as unimpaired on both the gold standard and the screen. PPP relates to specificity and is defined as the probability that an individual
has HAND given their positive screen result. NPP relates to sensitivity and is the probability that an individual does not have HAND given their negative
screen result. a proportion; b manually calculated; c values reported; d based on test scores only; e based on a cutoff score of 12 or less; f “any
neurocognitive impairment”; g sample excluded ANI category
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observed with core HAND domains, they were often also
related to other domains (e.g. visuoconstruction) to a similar
magnitude.
Discussion
The search for an optimal screening tool in HIV infection is
ongoing and remains a major challenge [41]. In keeping
with current recommendations regarding reliable HAND
diagnosis [10], we propose that a key factor for optimal
HAND screen validation is the comparison to a gold stan-
dard comprehensive neuropsychological battery. Of the
initial 35 studies identified that screened for HAND, 19
(54 %) were compared to a neuropsychological gold
standard.
Among those, there was substantial variation in six
key factors that hindered optimal screen validation and
straightforward interpretation of the literature. These
were:
1. Inclusion/non-inclusion of some HIV+individuals with-
out an optimal rationale
2. Lack of assessment of screening tool construct validity
3. Variation in overall gold standard impairment rate and use
of non-standard definitions of impairment
4. Lack of reporting screen overall impairment rate and
variation in screen impairment definition with no optimal
statistical rationale
5. Inclusion/non-inclusion of a control (HIV-) group; and
6. Lack of reporting of important HIV and/or demographic
characteristics.
To aid in selecting an optimal screen, all analyses were
ranked by optimal sensitivity and specificity, and those with
both indexes greater than 70 % were presented separately (see
Table 3). A cut-off of 70 % was selected to yield a demanding
threshold for type I and type II errors simultaneously.
Depending on the clinical context, however, lower ranked
screens such as those with high sensitivity and low specificity
may be more relevant and were also included in Table 2 as a
guide for selecting an appropriate screen. Caution is advised,






Cut-off Sample Sensitivity Specificity Accuracy
[40] Morgan HDS 43a - T<40 HAD only 93 73 -
[31] Moore 4 NP tests 19b - 4 tests T <40, or Entire sample 87 87 -
2 tests T <40+1 test T <35, or
2 tests T <35,
or 1 test T <40+1 test T<30,
or 1 test T <25
[31] Moore 3 NP tests 19b - 3 tests T <40 or Entire sample 87 76 -
1 testT <40+1 test T <35, or
1 test T<30
[25] Cysique CogState 62a 62a - Entire sample 81 70 -
[23] Carey NP tests (HVLT-R & ndGP) 29a 34a T <40 on 1 test or T<35 on 2 tests Entire sample 78 85 83
[40] Morgan HDS 43a - T<40 MND only 77 73 -
[23] Carey NP tests (HVLT-R & Cod) 29a - T <40 on 1 test or T<35 on 2 tests Entire sample 75 92 87
[31] Moore 2 NP tests 19b - 2 tests T <40 or Entire sample 73 83 -
1 test T ≤35
[29] Sacktor
(American)
IHDS 38a - ≤10.5 Entire sample 71 79 -
[21] Becker CAMCI 31a 30b - Entire samplec 72 98 -
Consideration of the sample in question is necessary for proper screen selection. See reference list for numbered studies. Rounded to nearest whole value.
Ordered with balance of highest sensitivity and specificity. NP = neuropsychological. IR = Impairment rate. Accuracy = overall correct classification
accuracy. ‘-‘ = not reported. Sensitivity refers to the proportion of individuals identified as impaired on both the gold standard and the screen. Specificity
refers to the proportion of individuals identified as unimpaired on both the gold standard and the screen. HAD =HIVAssociated Dementia.MND=Mild
Neurocognitive Disorder. HVLR-R = Hopkins Verbal Learning Test, revised. ndGP= nondominant hand Grooved Pegboard. Cod = Coding. a manually
calculated; b values reported; c sample excluded ANI category
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however, when using screens that have sensitivity close to
chance level (50 % or less). For this reason, the MMSE
should not be used to assess HAND. Of note, only one
study assessed the longitudinal validity of a screening tool.
Consequently, the following recommendations apply to
cross-sectional studies that examined the validity of
screens, and it will be necessary to better establish the
longitudinal validity of any of the current screen included
in this review.
How to Best Interpret Criterion Validity
It is recommended that attention be paid to the characteristics
of the sample that the screen was validated in. In particular, it
is imperative that the level of clinical comorbidities (which
may or may not impact cognition), referral source (tertiary or
not), and the degree of HIV disease severity are comparable to
the context that the screen is to be used in, as greater levels of
comorbidities and advanced HIV (more common in tertiary
settings) are likely to lead to a higher base rate of impairment
and inflated criterion validity when compared to the wider
HIV+community.
It is also important to select a screen that has been validated
against a standard definition of impairment, and preferably the
current AANHAND nomenclature [10], as these criteria have
a robust statistical grounding upon which to define impair-
ment and increases comparability across studies [11••]. The
sole use of neuropsychological test scores without assessment
of functional status precludes the use of the AAN criteria and
the discrimination of ANI from MND [10]. Caution is also
warrented if the validation study excluded ANI, as this is the
most common form of HIV-related cognitive impairment in
the cART era [7••]. Although the validity of ANI as a sub-
clinical form of HAND was initially equivocal, cumulative
evidence now suggests it to be a valid neuropathological
entity [42] that is predictive of further cognitive decline
[11••]. Finally, as the ability to accurately calculate sensi-
tivity and specificity for a test directly depends on the
correct use of base rates [43], artificial manipulation of
the base-rate impairment invalidates the standard defini-
tions of HAND and results in an unreliable estimation of
impairment in the sample.
Strengths and Weaknesses of Screens with Highest Criterion
Validity
The screen that exhibited the highest criterion validity was
the demographically adjusted HDS [40]. However, this
occurred only when the subset of HAD was considered,
as the inclusion of MND and ANI resulted in inadequate
(chance-level) sensitivity and is therefore inappropriate for
use in the cART era where ANI is the most prevalent form
of HAND [7••]. Overall, the screens that examined short
neuropsychological test combinations [23, 31, 40] consis-
tently demonstrated the highest performing criterion valid-
ity. While such a finding would be expected, this method
may not be feasible in a busy clinical practice where time is
limited and where there may not be anyone qualified to
administer, and most importantly, to correctly score and
interpret such tests. As an additional barrier, for legal and
ethical reasons some tests can only be interpreted by a
qualified neuropsychologist.
Table 4 Reported correlations between screening measure and neuropsychological test and cognitive domain for the four studies
Highest Lowest
Study (screening measure) Domain (NP test) r Domain (NP test) r
[34] Joska (IHDS) Information processing speed (CT1) / memory (BVMT recall) .35a Executive function (CT2) .21a
[25] Cysique (CogState) Fine motor skill (GPd) .62b Visuoconstruction (RCFT copy) -.22c
[39] Smith (CalCAP mini) Executive function .43d Fine motor skill .22e
The follow studies did not report any characteristics for HIV+ group: Chalermchai et al., 2013, Sakamoto et al., 2013, Moore et al., 2012, Becker et al.
2011, Singh et al., 2008, Bottiggi et al., 2007, Carey et al., 2004, Ellis et al., 2005, Levine et al., 2011, Morgan et al., 2005, Richardson et al., 2005,
Sacktor et al., 2005 (American or Ugandan), Simioni et al., 2010, Skinner et al., 2009, Smith et al., 2003, Wonja et al., 2007. Only correlations that
reached statistical significance (p <.05) were reported. NP = Neuropsychological. r =Pearson’s correlation. IHDS = International HIV Dementia Scale.
CT1 = Colour Trails Test part 1. BVMT = Brief Visuospatial Memory Test. CT2 = Colour Trails Test part 2. GPn = Grooved Pegboard non-dominant




d Summary deficit score of Halstead Category Test, Trail Making Test part B, and Stroop Color Word Interference Test
e Choice RT 4 (RT)
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The CogState computerised battery [25] was as good as
paired neuropsychological tests. However, this result may
have been inflated by the advanced HIV disease stage of all
participants and associated high base rate of impairment.
Moreover, the specific battery lacked a verbal list-learning
task of memory which has been shown to be particularly
sensitive to the deficits characterising mild HAND [44]. That
withstanding, a key benefit of using a computerised task is that
compared to neuropsychological tests, it requires minimal
skill regarding administration, interpretation, and scoring. A
caveat to this however, is that the final interpretation will
likely need to be monitored by a neuropsychologist as the
battery is sensitive to not only HAND, but cognitive impair-
ment in general. Lastly, although the CAMCI demonstrated
one of the highest criterion validity indexes [21], the sample
excluded those with ANI, which both artificially inflated
the sensitivity and rendered the screen non-usable to detect
ANI. In addition, replication of the study is impossible as
the individual neuropsychological tests employed were not
reported.
Finally, all HAND screen validation studies failed to in-
clude a measure of IADL status in their screening measure.
This remains a key limitation as it precludes optimal
operationalisation of the current HAND criteria when using
the screen and its ability to differentiate between ANI and
MND [10].
Construct Validity
Construct validity was reported in a minority of studies (3/19
or 16 %). Neglecting to report such data results in an inability
to determine which tests are more/less valuable as screening
measures and limits progression in the field. There are two
possible explanations for the failure to report construct valid-
ity. First, most studies used samples of convenience, rendering
it probable that the test battery was not selected to compare
with a screen. Second, the majority of screens were initially
developed in the pre cART era. As such, the construct validity
may have been assumed which is problematic as in the pre-
cART era HAD was more prevalent. Construct validity is
therefore a vital index of validity as HAND has become
milder.
In those studies that reported construct validity, it was
found that nearly all associations were within the small to
moderate range, and none consistently and uniquely associat-
ed with core HAND domains. One explanation of this finding
is that these screens measure different facets of cognition
compared to traditional neuropsychological tests. Such an
assertion is consistent with previous findings [28] that used
factor analysis to demonstrate that the subtests from the
CalCAP screen loaded on separate factors to neuropsycholog-
ical tests, and such an interpretation is reinforced by the
finding that the screens that used neuropsychological test
pairings were among the most sensitive and specific. This
argues for renewed effort and resources to be directed toward
tackling this clinical research question. One possible means to
improve criterion validity of computerised screens is to in-
clude reaction time measures in the gold standard neuropsy-
chological battery (e.g. [45]).
Key Clinical and Demographic Information
Several studies did not adequately report all key clinical data
and demographic variables for their sample. This hinders a
straightforward interpretation of the clinical relevance of the
findings as these factors have likely impacted the level of gold
standard and screen impairment rate and the related level of
criterion validity. Caution is therefore recommended when
using the optimal screens highlighted in this review. Prior to
the use of any screen, it should be ensured that the population
of interest is adequately represented by the validation sample.
Recommendations for Optimal Validation of a HAND
Screening Procedure
From the analysis of existing studies several key aspects should
be consideredwhen developing and validating aHAND screen-
ing procedure. Prospective studies are required which adopt the
following recommendations:
1. Selection of adequate screen outcomemeasures that target
core HAND domains that are known to be predominantly
affected in the cART era.
2. Assess IADL with a standard instrument to allow screen
operationalisation of the AAN criteria. It should also be
noted that IADL is best interpreted in the context of
concomitant assessment of mood status [46].
3. Comparison of the screen to a comprehensive neuropsy-
chological gold standard (i.e. assessment of core HAND
domains in addition to fine motor skill, language, visuo-
spatial skills, and premorbid ability) in combination with
IADL status, to improve the reliability of base-rate of
impairment.
4. Use of the most representative sample of the HIV popu-
lation within one country or country region (not exclu-
sively tertiary healthcare samples, for example).
5. The inclusion of a control (HIV-) group with similar
characteristics to optimally assess HAND specificity.
6. Explicit rationale for screen impairment criteria.
7. Reporting of all standard criterion validity indexes.
8. Reporting of construct validity.
9. Assessment of the screen feasibility in practice.
10. Assess the longitudinal validity of the screening tool
including correction for practice effects.
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Recommendations for Optimal use of HAND Screening,
Patient Results and Feedback in HIV Primary Care
The overarching suggestion is that rather than seeking to
implement a screening tool in isolation, a procedure should
instead be applied to yield an optimal indication of the need of
each patient for further neurological examination. This deci-
sion is based on whether there is:
1. HIV-related neurocognitive impairment on the cognitive
screen tool, and if so, to what degree;
2. Whether any other neuropsychiatric confounds (based on
standardised questionnaires or clinical interviews regard-
ing mood/substance use and medical history) may con-
tribute to the presence or severity of neurocognitive im-
pairment, and
3. Whether the detected neurocognitive impairment interferes
significantly with everyday functioning (i.e., IADL status).
If any of the above three points are present in combination or
in isolation, the primary care physician should refer the patient
to a neurologist with an accompanying referral letter detailing
the aforementioned information. Importantly, as the AAN
HAND criteria [10] outlines, the presence of neurocognitive
impairment alone is not sufficient to reach a diagnosis of
HAND. This is particularly the case when cognitive function
has been assessed via a brief screen. It is therefore only follow-
ing neurological examination in combination with further clin-
ical investigation including brain imaging, extensive blood test
panel and if possible extensive cerebrospinal fluid panel, and
careful recording of neurological history, that a HAND diag-
nosis can be reached [10].
The success of any HAND screening procedure at the prima-
ry care level also requires the practice to have necessary re-
sources available to optimally train the non-neuropsychologist
(e.g. nurses) in administration of the screening assessment, as
well as for conducting long-term quality control on test admin-
istration and neurocognitive and clinical data handling. It would
also be optimal for a key primary care physician within the clinic
with additional training in HIV neurology to oversee the imple-
mentation of this process. To adequately deal with complex cases
(e.g. withmultiple comorbid factors such asmood and substance
disorders), and to manage long-term quality assurance, it is also
advised that the lead primary care physician seeks collaboration
with a senior neuropsychologist.
One final but vital aspect to consider is the dissemination of
results to the patient. As emphasised above, results from a
screening procedure serve only to indicate the need for further
neurological examination. It is therefore strongly advised that
feedback from the HAND screen is disseminated in specifical-
ly these terms only. As the screening procedure is not diag-
nostic, mention of the presence or absence of “neurocognitive
impairment” is not appropriate. Additionally, if co-morbid life-
threatening conditions are present (e.g. major depressive
disorder with suicidal ideations or severe cardiac health issues)
treatment of these issues via psychiatric or specialist interven-
tion should take precedence over that of HAND. Once these
issues have been addressed and are stable, the patient should
then be re-assessed on the screen and directed for neurological
care as necessary.
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